ZYNERBA PHARMACEUTICALS INC (ZYNE)
US98986X1090 - Common Stock
Why Shares of Harmony Bioscience Are Falling on Friday
The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, CEQP, CELL, ZYNE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, ZYNE, HEP, CEQP
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony
/PRNewswire/ -- Ademi LLP is investigating Zynerba (Nasdaq: ZYNE) for possible breaches of fiduciary duty and other violations of law in its transaction with...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, AVID, ZYNE, HEP
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, DBTX, VRTV, ZYNE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications.
Zynerba stock surges on buyout deal with Harmony Biosciences
Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. Read more here.
Harmony Biosciences to acquire Zynerba for up to $200M cash (NASDAQ:ZYNE)
Harmony Biosciences (HRMY) traded lower pre-market Monday after announcing an agreement to acquire Zynerba Pharmaceuticals (ZYNE) for up to $200M cash. Read more here.
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...